| Literature DB >> 35564468 |
Agnieszka Dawczak-Dębicka1, Joanna Kufel-Grabowska2, Mikołaj Bartoszkiewicz3, Adrian Perdyan4, Jacek Jassem5.
Abstract
Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Increasing patients' awareness and providing easier access to public information result in greater interest in alternative anticancer or unproven supportive therapies. Fear of cancer and limited trust in the treating physician are also important reasons leading patients to seek these methods. Trust and good communication are essential to achieving truthful collaboration between physicians and patients. Given the popularity of CAM, better knowledge about these alternative practices may help oncologists discuss this issue with their patients. This article objectively reviews the most common unconventional therapies used by cancer patients.Entities:
Keywords: alternative and complementary medicine; cancer; chlorella; hemp; ozone therapy; spirulina; turmeric; vitamin C; whole-body hyperthermia
Mesh:
Year: 2022 PMID: 35564468 PMCID: PMC9104744 DOI: 10.3390/ijerph19095071
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Animal and in vitro studies.
| Method | Authors | Major Findings |
|---|---|---|
|
| Azamai et al. (2009) [ | Antiproliferative activity in liver and colorectal cancer cells. |
| Lin et al. (2020) [ | Reduced bone marrow suppression after cisplatin. | |
|
| Govind et al. (2013) [ | Improved anticancer effect of doxorubicin. |
|
| Torres et al. (2011) [ | Increasing chemosensitivity of glioblastoma cells. |
| Gil et al. (2013) [ | Antiproliferative effects in breast, uterus, gastric, colorectal, pancreatic and prostate cancer, lung adenocarcinoma and lymphoma cell lines. | |
|
| Khacha-ananda et al. [ | Cytotoxic effect in breast, cervical, skin, gastric, and prostate cancer and leukemia cells; protective effect on the DNA of healthy cells. |
|
| Chen et al. (2012) [ | High doses inhibit growth of prostate, colon, and pancreatic cancer, as well as mesothelioma cell lines. |
|
| Streyczek et al. (2022), [ | Antioxidant and anti-inflammatory effects. |
| Sreekanth et al. (2011) [ | Increasing sensitivity of cancer cells to cisplatin, 5-fluorouracil, paclitaxel, and radiotherapy. | |
|
| Vincenzo et al. (2017) [ | Potentiation of fluorouracil effect in colorectal cancer. |
| Ouhtit et al. (2014) [ | Anti-angiogenic effect in breast and non-small-cell lung cancer cell lines. | |
|
| No studies identified. | |
|
| No studies identified. | |
|
| Sadhu et al. (2017) [ | Inhibiting invasion of cancer cells and tumor proliferation in mouse models. |
|
| Li et al. (2021) [ | Blocking TGF-beta, HMGB1, ERK1/2, and AKT signaling, leading to the inhibition of epithelial-mesenchymal transition and radiosensitization of breast cancer cells. |
|
| Eberhard et al. (2009), Yuan et al. (2004) | High-cell-permeability ICs such as CPX (ciclopirox olamine) and Dp44mT have been identified and designed. |
|
| Frenkel et al. (2015) [ | Inconsistent results of preclinical studies and randomized double-blind, placebo-controlled clinical trials. |
Effects in humans.
| Method | Authors | Major Findings |
|---|---|---|
|
| Noguchi et al. (2014) [ | Decreased severity of chronic weakness and skin dryness. |
|
| Shakib et al. (2015) [ | Beneficial effect in combination with chlorambucil in a patient with B-CLL leukemia. |
|
| Pagano et al. (2022), [ | Reduced severity of nausea and vomiting associated with chemotherapy; analgesic effects. |
|
| Münstedt et al. (2019) [ | Effective and safe in preventing and treating oral mucositis caused by radiotherapy or chemotherapy. |
|
| Welsh et al. (2013) [ | Reducing chemotherapy-related symptoms such as fatigue, nausea, vomiting, and loss of appetite. |
|
| He et al. (2011) [ | Reducing weight loss and decreasing serum inflammatory parameters in patients with colorectal cancer; reducing tumor size. |
|
| Tirelli et al. (2018) [ | Reducing nausea, vomiting, infections, hair loss, and weakness caused by anticancer treatment. |
|
| Mathew et al. (1995) [ | Chemopreventive effect in people chewing tobacco; recurrence of oral leukoplakia with discontinued administration. |
|
| Lassche et al. (2019) [ | No convincing evidence of clinical efficacy. |
|
| Ashby et al. (2021) [ | Reduction of tumor-related and postoperative pain. |
| Zhang et al. (2021) [ | Alleviating nausea, vomiting, and weakness; improving quality of life. | |
|
| Rose et al. (2007) [ | No clinical effect in combination with pegylated liposomal doxorubicin in patients with advanced ovarian cancer. |
|
| No studies identified. | |
|
| Khan et al. (2009) [ | No convincing evidence of clinical efficacy. |
|
| Frenkel et al. (2015) [ | Negative results of large clinical studies. |
Side effects and contraindications.
| Method | Authors | Major Findings |
|---|---|---|
|
| Noguchi et al. (2014) [ | Constipation. |
|
| No adverse events. | |
|
| Cohen et al. (2019) [ | Tachycardia, hypotension, anxiety, euphoria, muscle relaxation, impaired cognitive functions. |
| Gil et al. (2013) [ | Withdrawal symptoms: irritability, restlessness, nausea, insomnia. | |
|
| No adverse events. | |
|
| Klimant et al. (2018) [ | Infused shortly before chemotherapy may cause adverse interactions (e.g., red blood cell hemolytic crisis). |
| Lo et al. (2020) [ | Risk of hemolysis with intravenous infusion; contraindicated in patients with glucose-6-phosphate dehydrogenase deficiency. | |
|
| Jantan et al. (2008) [ | Interactions with antiplatelet agents, doxorubicin, or tacrolimus, affecting the activity of cytochrome P450 enzymes. |
|
| Bocci et al. (2010) [ | Contraindicated in pregnant women, patients with severe cardiovascular diseases (e.g., after myocardial infarction), hyperthyroidism, and thrombocytopenia; special care in patients with asthma. |
|
| Mathew et al. (1995) [ | No adverse events. |
|
| Lassche et al. (2019) [ | Grade 3/4 ventricular cardiac arrhythmias, dermal complications, nephrotoxicity. |
|
| Höxtermann et al. (2022) [ | Contraindicated in patients with hemophilia or administered anticoagulants. Special care in patients with skin diseases. |
|
| Kavanagh et al. (2010) [ | Nausea, vomiting, rash, fatigue, neutropenia, leukopenia, anemia. |
|
| El Barky et al. (2017) [ | No adverse effects with moderate doses. |
|
| Komoto et al. (2021) [ | No severe adverse events. |
|
| No adverse events reported. |